---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-204056"
form_type: "8-K"
ticker: "NUVB"
cik: "0001811063"
company_name: "Nuvation Bio Inc."
filed_at: "2026-05-04T23:59:59+00:00"
generated_at: "2026-05-14T23:59:11.173244+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Nuvation Bio Q1 2026 net product revenue $18.5M; net income $5.4M vs loss year ago

## Summary
- Net product revenue $18.5M from IBTROZI; net income $5.4M ($0.02 basic EPS) vs net loss $53.2M year ago.
- Collaboration revenue $64.7M including $58.7M upfront from Eisai; cash and securities $533.7M.
- Over 600 patients started IBTROZI since launch; majority of ~200 new Q1 patients were TKI-naïve.
- Acquired Japan rights to safusidenib from Daiichi Sankyo, gaining full global development and commercialization rights.
- Updated pooled TRUST data at AACR: mPFS 46.1 months, mDOR 49.7 months in TKI-naïve ROS1+ NSCLC.

## SEC filing metadata
- accession: 0001193125-26-204056
- form_type: 8-K
- ticker: NUVB
- cik: 0001811063
- company_name: Nuvation Bio Inc.
- filed_at: 2026-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1811063/000119312526204056/0001193125-26-204056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1811063/000119312526204056/d132166d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-204056
- JSON: https://secwatch.observer/filing/0001193125-26-204056.json
- Plain text: https://secwatch.observer/filing/0001193125-26-204056.txt

## Key facts
- Earnings Releases
  Nuvation Bio Inc. reported first quarter ended March 31, 2026 results: revenue $18.5 million.
  - Period: first quarter ended March 31, 2026
  - Revenue: $18.5 million
  - Result: reported results
  source text: Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update Achieved $18.5 million in first quarter of 2026 net product revenues for IBTROZI
  evidence_url: https://www.sec.gov/Archives/edgar/data/1811063/000119312526204056/0001193125-26-204056-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.